BCA101X301 - A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1- positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BCA101X301)

Principal Investigator

Dr Rebecca Shakir

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1011448